DiaMedica Therapeutics Inc
DMAC
$2.45
Closing
▲1.24%
1D
▼-13.73%
YTD
Market cap
$93.00M
52 week high
$4.70
52 week low
$1.53
Volume
2,474
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$93.00M
Analysts' Rating
BUY
Price Target (Mean)
8.33333
Total Analysts
3
P/E
Operating Margin
0.00%
Beta
1.78
Revenue Growth (Annual)
0.00%
52 week high
$4.70
52 week low
$1.53
Div. Yield
%
EPS Annual Growth
-25.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The Company’s lead product, DM199, is an active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein for the treatment of AIS and CKD, including hypertensive nephrosclerosis (hypertension). KLK1 is a serine protease (protein) that plays a role in the regulation of diverse physiological processes, including blood flow, inflammation, fibrosis, oxidative stress, and neurogenesis, via a molecular mechanism that increases the production of nitric oxide and prostaglandin. It has also identified a potential treatment for inflammatory diseases, DM300, which is in the early preclinical stage of development.
